Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dianthus Therapeutics (DNTH) Research & Development (2017 - 2025)

Dianthus Therapeutics (DNTH) has 7 years of Research & Development data on record, last reported at $32.5 million in Q3 2025.

  • For Q3 2025, Research & Development rose 27.19% year-over-year to $32.5 million; the TTM value through Sep 2025 reached $117.0 million, up 78.62%, while the annual FY2024 figure was $87.9 million, 167.65% up from the prior year.
  • Research & Development reached $32.5 million in Q3 2025 per DNTH's latest filing, up from $26.3 million in the prior quarter.
  • Across five years, Research & Development topped out at $32.5 million in Q3 2025 and bottomed at -$4.4 million in Q3 2022.
  • Average Research & Development over 4 years is $16.0 million, with a median of $13.1 million recorded in 2024.
  • The widest YoY moves for Research & Development: up 280.01% in 2023, down 64.66% in 2023.
  • A 4-year view of Research & Development shows it stood at $9.8 million in 2022, then fell by 10.68% to $8.8 million in 2023, then surged by 255.4% to $31.2 million in 2024, then grew by 4.1% to $32.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Research & Development were $32.5 million in Q3 2025, $26.3 million in Q2 2025, and $27.0 million in Q1 2025.